5-HT1A RECEPTOR SUBTYPE AGONIST

• US 20090012098A1
• Filed: 08/29/2008
• Published: 01/08/2009
• Est. Priority Date: 01/29/2001
• Status: Active Grant

• Current Assignee: Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Original Assignee: Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Inventors: Kikuchi, Tetsuro, Tottori, Katsura, Uwahodo, Yasufumi, Hirose, Tsuyoshi, Jordan, Shaun
• Granted Patent: US 8,623,874 B2
• Time in Patent Office: Days
• US Class Current: 514/253.70
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4704 2-Quinolinones, e.g. carbostyril
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/08 for nausea, cinetosis or vertigo; Antiemetics
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT_1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1)

wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

Claims

1. A method of treating a patient suffering from a neurodegenerative disease or cognitive impairment caused by neurodegenerative disease, which comprises administering to said patient a therapeutically effective amount of a carbostyril compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein said patient is a mammal:

wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

2. The method of claim 1, wherein the disorder is a neurodegenerative disease.

3. The method of claim 1, wherein the disorder is cognitive impairment caused by neurodegenerative disease.

4. The method of claim 2 wherein the disorder is a neurodegenerative disease.

5. The method of claim 3 wherein the neurodegenerative disease is Alzheimer'"'"'s disease.

6. The method of claim 1 wherein the neurodegenerative disease is Alzheimer'"'"'s disease or Parkinson'"'"'s disease.

7. The method of claim 3, wherein the neurodegenerative disease is Parkinson'"'"'s disease.

8. The method according to any one of claims 1-7 wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxyl}-3,4-dihydrocarbostyril.